Maria Constantinou, MD
Hematology & Oncology · Providence, RINPI 1407999444
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $163 of the $248 with a category attached, or 65.7%. E.r. Squibb & Sons, L.L.C. accounts for 95.2% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hematology & oncology clinicians in RI, where the typical reported total is $376.
Across 6 payments — averaging $41.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$236
- Gilead$12
Across 39 payments — averaging $3511.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$103K
- Genentech, Inc.$27K
- AbbVie$6K
What the payments were for
- Travel & lodging$7329%
- Food & beverage$16366%
- Education$125%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 5 | $236 |
| Gilead | 1 | $12 |
How this compares
$248 in reported general payments places this provider in the 40th percentile of 68 hematology & oncology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 11 | $163,382 |
| Anastrozole | 57 | $926 |
| Letrozole | 51 | $749 |
| Tamoxifen Citrate | 12 | $270 |
| Prochlorperazine Maleate | 11 | $192 |
| Ondansetron Hcl | 26 | $169 |
| Levothyroxine Sodium | 11 | $160 |
| Triamcinolone Acetonide | 21 | $135 |
| Alendronate Sodium | 14 | $132 |
| Prednisone | 26 | $103 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Providence
- William SikovProvidence$156K
- Ritesh RathoreProvidence$148K
- Anthony MegaProvidence$65K
- Adam OlszewskiProvidence$63K
- Hina KhanProvidence$34K
- Peter BarthProvidence$29K
- Thomas OllilaProvidence$19K
- John ReaganProvidence$18K
- Jennifer GassProvidence$16K
- Matthew HadfieldProvidence$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.